Uncover key drivers, emerging technologies, and competitive movements shaping the calcitonin gene-related peptide (cgrp) inhibitors market from 2026–2035 with trusted insights from The Business Research Company
What total market size is anticipated for the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market in 2030?
The calcitonin gene-related peptide (CGRP) inhibitors market has experienced robust expansion over recent years. It is anticipated to expand from $3.14 billion in 2025 to $3.45 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.9%. This historical growth can be linked to factors such as the increasing incidence of migraine disorders, the shortcomings of existing migraine treatments, the growing clinical validation of the CGRP pathway, heightened adoption by neurologists, and supportive reimbursement frameworks in developed regions.
The calcitonin gene-related peptide (cgrp) inhibitors market is anticipated to show significant expansion in the upcoming years, with its size projected to reach $5.02 billion in 2030, growing at a compound annual growth rate (CAGR) of 9.8%. This growth in the forecast period can be attributed to an expanding patient pool suffering from chronic migraines, the pipeline’s growth for oral CGRP inhibitors, an increasing demand for long-term migraine prevention, improved adherence by patients to targeted therapies, and broader access in emerging markets. Major developments expected in this period include the rising adoption of targeted migraine therapies, an increasing shift towards preventive approaches for migraine treatment, a growing preference for non-opioid pain management solutions, the expansion of oral CGRP small molecule inhibitors, and enhanced awareness and diagnosis of chronic migraine.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp
What Drivers Are Influencing Production Trends In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The expanding occurrence of migraine is anticipated to fuel the expansion of the calcitonin gene-related peptide (CGRP) inhibitors market moving ahead. Migraine is characterized as a severe headache often leading to pulsating pain, frequently localized to one side of the head, and commonly associated with nausea, vomiting, and heightened sensitivity to light and sound. The rising incidence of migraine is linked to escalating stress levels, as sustained stress activates specific neural pathways. Calcitonin gene-related peptide (CGRP) inhibitors contribute significantly to migraine management by providing a targeted, prophylactic approach that is suitable for both acute and long-term care. These inhibitors effectively decrease the frequency and intensity of headaches through efficient CGRP receptor blockade, thereby enhancing patients’ quality of life and their ability to perform daily activities. As an illustration, in January 2023, a report from the US-based health information institution, the National Library of Medicine, indicated that the global prevalence of migraine ranges from 14% to 15%, accounting for 4.9% of the global disease burden. Consequently, the growing prevalence of migraine is propelling the growth of the calcitonin gene-related peptide (CGRP) inhibitors market.
Which Segments Are Gaining Traction In The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The calcitonin gene-related peptide (cgrp) inhibitors market covered in this report is segmented –
1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies
Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems
What Trends Are Driving The Growth Trajectory Of The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
Major companies in the calcitonin gene-related peptide (CGRP) inhibitors market are prioritizing the development of innovative products to gain approvals. These efforts include creating calcitonin gene-related peptide (CGRP) receptor antagonists to improve migraine treatment efficacy, expand therapeutic applications, and introduce more convenient administration methods like oral and intranasal formulations. A calcitonin gene-related peptide (CGRP) receptor antagonist is a medication that inhibits the calcitonin gene-related peptide (CGRP) receptor to block pain signaling related to migraines. For example, in April 2023, AbbVie Inc., a biotech company based in the US, received approval from the U.S. Food and Drug Administration (FDA) for QULIPTA (atogepant) for treating chronic migraine in adults. QULIPTA is an oral calcitonin gene-related peptide (CGRP) receptor antagonist that functions by blocking calcitonin gene-related peptide (CGRP) receptors, which are involved in the underlying mechanisms of migraine, thereby assisting in preventing migraine attacks.
Who Are The Primary Competitors In The Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
Major companies operating in the calcitonin gene-related peptide (cgrp) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.
Access The Complete Report For Deeper Market Insights:
Which Global Regions Are Shaping The Competitive Landscape Of The Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (cgrp) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp
Browse Through More Reports Similar to the Global Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market 2026, By The Business Research Company
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Peptide Based Metabolic Disorders Therapeutics Market Report 2026
Cc Chemokine Receptor Type 5 Market Report 2026
https://www.thebusinessresearchcompany.com/report/cc-chemokine-receptor-type-5-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model